GHK-Cu Supports collagen production, skin health, hair support, and tissue regeneration
Weight loss of 3-5% is typical by this point for most patients
The relationship between semaglutide dosage and appetite suppression follows a dose-response curve, but individual variability significantly affects outcomes
Understanding that constipation on GLP-1 therapy is a predictable, manageable side effectnot a reason to stop treatmenthelps you stay committed to your weight loss goals
Tirzepatide (Mounjaro, Zepbound) Strengths: Highest efficacy for both glucose control and weight loss Dual mechanism (GLP-1 + GIP) may provide unique benefits Once-weekly dosing Generally well-tolerated Considerations: Higher cost than semaglutide Less long-term safety data (newer medication) Cardiovascular outcome trial not yet complete (though expected to be positive) Best for: Patients prioritizing maximum weight loss
Who it suits best: People who want comprehensive blood testing and diagnostics as part of their weight-loss programme, and who value a data-driven approach to health beyond just weight loss